Stephan Grupp MD PhD
Stephan Grupp MD PhD
Explore linked clinical trials.8 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma | Eye Diseases, Hereditary, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, extraocular retinoblastoma, eye disorder, neoplasm, neuroblastoma, neuroepithelial neoplasm, ocular cancer, primitive neuroectodermal tumor, retinal cancer, retinal disorder, retinoblastoma | Enrolling by invitation | Phase 1 | 2026-08-14 | NCT05650749 | |
| CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-07-07 | NCT07464951 | |
| Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell leukemia, T-cell non-Hodgkin lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-07-07 | NCT06934382 | |
| PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-07-01 | NCT07007117 | |
| Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-05-26 | NCT05480449 | |
| Co-administration of CART22-65s and huCART19 for B-ALL | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT05674175 | |
| Orphan Indications for CD19 Redirected Autologous T Cells | Infants With Very High Risk KMT2A B-ALL; Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation; Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL | Recruiting | Phase 2 | 2026-03-06 | NCT04276870 | |
| Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, skin disorder, systemic lupus erythematosus, systemic sclerosis | Recruiting | Phase 2 | 2025-10-14 | NCT05029336 |